Wedbush Has Positive Outlook for PTGX Q1 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Protagonist Therapeutics in a research report issued on Tuesday, November 19th. Wedbush analyst Y. Zhong now expects that the company will post earnings of $1.92 per share for the quarter, up from their previous forecast of ($0.64). Wedbush has a “Outperform” rating and a $58.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.28 per share. Wedbush also issued estimates for Protagonist Therapeutics’ FY2025 earnings at ($0.16) EPS.

Several other analysts have also issued reports on the company. JMP Securities cut their target price on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 7th. StockNews.com raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Truist Financial initiated coverage on Protagonist Therapeutics in a research note on Monday, September 9th. They set a “buy” rating and a $60.00 target price on the stock. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. Finally, JPMorgan Chase & Co. upped their price target on Protagonist Therapeutics from $39.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Stock Up 2.5 %

NASDAQ PTGX opened at $41.65 on Thursday. The stock’s 50-day simple moving average is $45.34 and its two-hundred day simple moving average is $39.00. Protagonist Therapeutics has a twelve month low of $16.80 and a twelve month high of $48.89. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of 15.83 and a beta of 2.17.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 1,906 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the sale, the insider now owns 46,444 shares in the company, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Asif Ali sold 14,203 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the sale, the chief financial officer now owns 34,960 shares of the company’s stock, valued at $1,555,370.40. This represents a 28.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,109 shares of company stock worth $1,069,999. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors have recently bought and sold shares of PTGX. GAMMA Investing LLC grew its position in Protagonist Therapeutics by 749.2% in the third quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after acquiring an additional 487 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth approximately $43,000. Russell Investments Group Ltd. bought a new position in shares of Protagonist Therapeutics during the 1st quarter valued at approximately $35,000. CWM LLC raised its holdings in Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock valued at $57,000 after buying an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in Protagonist Therapeutics in the third quarter worth $69,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.